Spyre Therapeutics (FRA:3920) Dividends per Share: €0.00 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3920 Spyre Therapeutics Inc FRA:3920
29 GF Score
Price €87.50
GF Value €1.98
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics Dividends per Share?

Spyre Therapeutics FRA:3920 +1.16% 29 Dividends per Share is €0.00 as of Mar. 2026. GuruFocus rates FRA:3920 with a GF Score™ of 29/100 and a GF Value™ of €1.98 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Spyre Therapeutics's dividends per share for the three months ended in Mar. 2026 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2026 was 0.00. As of today, Spyre Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Spyre Therapeutics  (FRA:3920) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Spyre Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ -0.97
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics Dividends per Share Related Terms

Spyre Therapeutics Dividends per Share Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics Dividends per Share Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spyre Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:3920 vs CRNX, PTGX, PRAX: Dividends per Share Comparison

For the Biotechnology subindustry, Spyre Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spyre Therapeutics Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Dividend Yield % falls into.


FRA:3920
29GF Score
Spyre Therapeutics Inc FRA:3920
Dividends per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of €0.00 mean?
Spyre Therapeutics (FRA:3920) has a Dividends per Share of €0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Spyre Therapeutics and its competitors.
Is Spyre Therapeutics' Dividends per Share too high?
Spyre Therapeutics' current Dividends per Share is €0.00. Overall, Spyre Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Dividends per Share compare to CRNX and PTGX?
Spyre Therapeutics' Dividends per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current Dividends per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spyre Therapeutics (FRA:3920) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.98, compared to a current price of €87.50 — trading 4319.2% above its estimated fair value. The current Dividends per Share is €0.00. Spyre Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current Dividends per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spyre Therapeutics (FRA:3920) Overvalued in 2026?

Based on GuruFocus' analysis, Spyre Therapeutics stock appears to be overvalued. The current stock price of €87.50 is trading 4319.2% above its estimated GF Value™ of €1.98. GuruFocus considers Spyre Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:3920:

  • Dividends per Share: €0.00
  • GF Value™: €1.98 vs. price of €87.50 (4319.2% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the FRA:3920 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
29GF Score

Get the complete analysis for FRA:3920

Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€87.50
Price
€1.98
GF Value